Comprehensive review of the psychiatric uses of valproate

Journal of Clinical Psychopharmacology

Volumn 20, Issue 1 SUPPL., 2000, Pages

  Davis, Lori L ^a,b   Ryan, William ^b   Adinoff, Bryon ^c,d   Petty, Frederick ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; IMIPRAMINE; NEUROLEPTIC AGENT; PAROXETINE; PHENELZINE; THIORIDAZINE; VALPROATE SEMISODIUM; VALPROIC ACID;

AFFECTIVE NEUROSIS; AGITATION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANTICONVULSANT ACTIVITY; ASTHENIA; CLINICAL TRIAL; COMORBIDITY; DEMENTIA; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTROENCEPHALOGRAM; HAIR LOSS; HEADACHE; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOSIS; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; TREMOR; VERTIGO;

ANTICONVULSANTS; ANTIMANIC AGENTS; ANXIETY DISORDERS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MOOD DISORDERS; PREGNANCY; PSYCHOTIC DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; VALPROIC ACID;

EID: 0033972320     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200002001-00001     Document Type: Review

References (204)

1. Lambert PA. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984:33-44
2. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271:918-24.
3. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992;149:108-11.
4. Clothier J, Swann AC, Freeman T. Dysphoric mania. J Clin Psychopharmacol 1992;12[suppl 1]:13S-16S.
5. Pope HG, McElroy SL, Keck PE, Hudson JI. Valproate in the treatment of acute mania. Arch Gen Psychiatry 1991;48:62-8.
6. McElroy SL, Keck PE, Pope HG, Hudson JI, Morris D. Correlates of antimanic response to valproate. Psychopharmacol Bull 1991; 27:127-33.
7. Emrich HM, Dose M, Vonzerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985;8:243-50.
8. Emrich HM, Altmann H, Dose M, Zerssen DV. Therapeutic effects of GABA-ergic drugs in affective disorders: a preliminary report. Pharmacol Biochem Behav 1983;19:369-72.
9. Emrich HM, Wolf R. Valproate treatment of mania. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:691-701.
10. Brennan MJW, Sandyk R, Borsook D. Use of sodium valproate in the management of affective disorders: basic and clinical aspects. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984:56-65.
11. Bowden CL, Davis J, Morris D, Swann A, Calabrese J, Lambert M, Goodnick P. Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania. Depress Anxiety 1997;6:26-30.
12. McElroy SL, Keck PE, Pope HG. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987; 7:16-24.
13. Calabrese JR, Rapport DJ, Kimmel SE, Reece B, Woyshville MJ. Rapid cycling bipolar disorder and its treatment with valproate. Can J Psychiatry 1993;38[suppl 2]:S57-S61.
14. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990;147:431-4.
15. Deltito JA, Levitan J, Damore J, Hajal F, Zambenedetti M. Naturalistic experience with the use of divalproex sodium on an inpatient unit for adolescent psychiatric patients. Acta Psychiatr Scand 1998;97:236-40.
16. Keck PE, McElroy SL, Tugrul KC, Bennett JA. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993; 54:305-8.
17. Brady KT, Sonne SC, Anton R, Ballenger JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry 1995;56:118-21.
18. Guscott R. Clinical experience with valproic acid in 22 patients with refractory bipolar mood disorder [letter]. Can J Psychiatry 1992;37:590.
19. Brown R. U.S. experience with valproate in manic depressive illness: a multicenter trial. J Clin Psychiatry 1989;50[suppl]:13-6.
20. McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996;57:142-6.
21. McElroy SL, Keck PE, Tugrul KC, Bennett JA. Valproate as a loading treatment in acute mania. Neuropsychobiology 1993;27:146-9.
22. Papatheodorou G, Kutcher SP. Divalproex sodium treatment in late adolescent and young adult acute mania. Psychopharmacol Bull 1993;29:213-9.
23. Papatheodorou G, Kutcher SP, Katic M, Szalai JP. The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: an open clinical trial. J Clin Psychopharmacol 1995;15:110-6.
24. Sharma V, Persad E, Mazmanian D, Karunaratne K. Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium. Can J Psychiatry 1993;38:137-9.
25. Puzynski S, Klosiewicz L. Valproic acid amide in the treatment of affective and schizoaffective disorders. J Affect Disord 1984;6: 115-21.
26. Vencovsky E, Soucek K, Kabes J. Prophylactic effect of dipropylacetamide in patients with bipolar affective disorder. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984:65-6.
27. Emrich HM, Dose M, Von Zerssen D. Action of sodium-valproate and of oxcarbazepine in patients with affective disorder. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984:45-55.
28. Jacobsen FM. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders and premenstrual syndrome. J Clin Psychiatry 1993;54:229-34.
29. Martinez JM, Russell JM, Hirschfeld RM. Tolerability of oral loading of divalproex sodium in the treatment of acute mania. Depress Anxiety 1998;7:83-6.
30. Noaghiul S, Narayan M, Nelson JC. Divalproex treatment of mania in elderly patients. Am J Geriatr Psychiatry 1998;6:257-62.
31. Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients. J Clin Psychiatry 1998;59:151-8.
32. McElroy SL, Keck PE, Pope HG, Hudson JI. Valproate in the treatment of rapid-cycling bipolar disorder. J Clin Psychopharmacol 1988;8:275-9.
33. Kando JC, Tohen M, Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 1994;55:255-7.
34. Kando JC, Tohen M, Castillo J, Zarate CA. The use of valproate in an elderly population with affective symptoms. J Clin Psychiatry 1996;57:238-40.
35. Frye MA, Altshuler LL, Szuba MP, Finch NN, Mintz J. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. J Clin Psychiatry 1996; 57:17-21.
36. McCoy L, Votolato NA, Schwarzkopf SB, Nasrallah HA. Clinical correlates of valproate augmentation in refractory bipolar disorder. Ann Clin Psychiatry 1993;5:29-33.
37. Schaff MR, Fawcett J, Zajecka JM. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry 1993;54: 10:380-4.
38. Tohen M, Castillo J, Pope HG, Herbstein J. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994;14:67-70.
39. Fogelson DL, Jacobson S, Sternbach H. A retrospective study of valproate in private psychiatric practice. Ann Clin Psychiatry 1991;3:315-20.
40. Hayes SG. Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry 1989;50[suppl]:35-9.
41. McElroy SL, Pope HG, Keck PE, Hudson JI. Treatment of psychiatric disorders with valproate: a series of 73 cases. Psychiatr Psychobiol 1988;3:81-5.
42. Stanton AM, Gerner RH. Valproate and lithium in mania: a chart review [abstract NR69:65]. From the New Research Program and Abstracts, American Psychiatric Association, 1991.
43. McFarland BH, Miller MR, Straumfjord AA. Valproate use in the older manic patient. J Clin Psychiatry 1990;51:479-81.
44. Lovett L, Watkins SE, Shaw DM. The use of alternative drug therapy in nine patients with recurrent affective disorder resistant to conventional prophylaxis. Biol Psychiatry 1986;21:1344-7.
45. Prasad AJ. the role of sodium valproate as an anti-manic agent. Pharmatherapeutica 1984;4:6-8.
46. Semadeni GW. Etude clinique de l'effet normothymique du dipropylacetamide. Acta Psychiatr Belg 1976;76:458-66.
47. Niedermier JA, Nasrallah HA. Clinical correlates of response to valproate in geriatric inpatients. Ann Clin Psychiatry 1998; 10:165-8.
48. Chen ST, Altshuler LL, Melnyk KA, Erhart SM, Miller E, Mintz J. Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study. J Clin Psychiatry 1999;60:181-6.
49. Post RM, Berrettini W, Uhde TW, Kellner C. Selective response to the anticonvulsant carbamazepine in manic-depressive illness: a case study. J Clin Psychopharmacol 1984;4:178-85.
50. Kmetz GF, McElroy SL, Collins DJ. Response of kleptomania and mixed mania to valproate. Am J Psychiatry 1997;154:580-1.
51. Yassa R, Cvejic J. Valproate in the treatment of posttraumatic bipolar disorder in a psychogeriatric patient. J Geriatr Psychiatry Neurol 1994;7:55-7.
52. Keck PE, McElroy SL, Vuckovic A, Friedman LM. Combined valproate and carbamazepine treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992;4:319-22.
53. Sharma V, Persad E. Augmentation of valproate with lithium in a case of rapid cycling affective disorder. Can J Psychiatry 1992;37: 584-5.
54. Risinger RC, Risby ED, Risch SC. Safety and efficacy of divalproex sodium in elderly bipolar patients [letter]. J Clin Psychiatry 1994;55:215.
55. Ketter TA, Pazzaglia PJ, Post RM. Synergy of carbamazepine and valproic acid in affective illness - case report and review of the literature. J Clin Psychopharmacol 1992;12:276-81.
56. Shliselberg N, Bosch JR, Herrera J. Valproic acid in the treatment of refractory bipolar disorder. J Clin Psychopharmacol 1990;10: 151-2.
57. Herridge PL, Pope HG. Treatment of bulimia and rapid-cycling bipolar disorder with sodium valproate: a case report. J Clin Psychopharmacol 1985;5:229-30.
58. Deltito JA. The effect of valproate on bipolar spectrum temperamental disorders. J Clin Psychiatry 1993;54:300-4.
59. Schaller JL, Behar D. Treatment of a case of comorbid bipolar disorder and attention-deficit hyperactivity disorder. J Neuropsychiatry Clin Neurosci 1998;10:235-6.
60. Schneider AL, Wilcox CS. Divalproate augmentation in lithium-resistant rapid cycling mania in four geriatric patients. J Affect Disord 1998;47:201-5.
61. Zarate CA, Tohen M, Baraibar G. Combined valproate or carbamazepine and electroconvulsive therapy. Ann Clin Psychiatry 1997;9:19-25.
62. Mordecai DJ, Sheikn JI, Glick ID. Divalproex for the treatment of geriatric bipolar disorder. Int J Geriatr Psychiatry 1999;14:494-6.
63. Solomon DA, Ryan CE, Keitner GI, Miller IW, Shea MT, Kazim A, Keller MB. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997;58:95-9.
64. Solomon DA, Keitner GI, Ryan CE, Miller IW. Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder a review. J Clin Psychopharmacol 1998;18:38-49.
65. Bowden CL, Swann AC, Calabrese JR, McElroy SL, Morris D, Petty F, Hirschfeld RM, Gyulai L. Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull 1997;33:693-9.
66. Denicoff KD, Smithjackson EE, Bryan AL, Ali SO, Post RM. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997;154:1456-8.
67. Suppes T, Rush AJ, Kraemer HC, Webb A. Treatment algorithm use to optimize management of symptomatic patients with a history of mania. J Clin Psychiatry 1998;59:89-96.
68. Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J, Dilsaver SC, Davis JM. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 1997;54: 37-42.
69. Davis LL, Kabel D, Patel D, Choate AD, Fosliennash C, Gurguis GNM, Kramer GL, Petty F. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 1996;32: 647-52.
70. Pies R, Adler DA, Ehrenberg BL. Sleep disorders and depression with atypical features: response to valproate. J Clin Psychopharmacol 1989;9:352-7.
71. Kemp LI. Sodium valproate as an antidepressant. Br J Psychiatry 1992;160:121-3.
72. Dave M. Antidepressant augmentation with valproate. Depression 1995;3:157-8.
73. Corrigan FM. Sodium valproate augmentation of fluoxetine or fluvoxamine effects. Biol Psychiatry 1992;31:1178-9.
74. Schatzberg AF. Phenomenology and treatment of agitation. J Clin Psychiatry Monogr 1999;17:12-4.
75. Petty F, Kramer GL, Fulton M, Davis L, Rush AJ. Stability of plasma GABA at four-year follow-up in patients with primary unipolar depression. Biol Psychiatry 1995;37:806-10.
76. Roy-Byrne PP, Mellman TA, Uhde TW. Biologic findings in panic disorder: neuroendocrine and sleep-related abnormalities. J Anxiety Disord 1988;2:17-30.
77. Keck PE, Taylor VE, Tugrul KC, McElroy SL, Bennett JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993;33:542-6.
78. Keck PE, McElroy SL, Tugrul KC, Bennett JA, Smith JMR. Antiepileptic drugs for the treatment of panic disorder. Neuropsychobiology 1993;27:150-3.
79. Keck PE, McElroy SL, Friedman LM. Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol 1992;12:36S-41S.
80. Marazziti D, Cassano GB. Valproic acid for panic disorder associated with multiple sclerosis. Am J Psychiatry 1996;153:6-7.
81. Roberts JM, Malcolm R, Santos AB. Treatment of panic disorder and comorbid substance abuse with divalproex sodium [letter]. Am J Psychiatry 1994;151:1521.
82. Brady KT, Sonne S, Lydiard RB. Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients. J Clin Psychopharmacol 1994;14:81-2.
83. McElroy SL, Keck PE, Lawrence JM. Treatment of panic disorder and benzodiazepine withdrawal with valproate. J Neuropsychiatry Clin Neurosci 1991;3:232-3.
84. Roy-Byrne PP. Anticonvulsants in anxiety and withdrawal syndromes: hypotheses for future research. In: McElroy SL, Pope HG, eds. Use of anticonvulsants in psychiatry: recent advances. Clifton, NJ: Oxford Health Care, 1988:155-68.
85. Ontiveros A, Fontaine R. Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 1992; 17:78-80.
86. Woodman CL, Noyes R. Panic disorder, treatment with valproate. J Clin Psychiatry 1994;55:134-6.
87. Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry 1990;35:248-50.
88. Primeau F, Fontaine R. GABAergic agents and panic disorder. Biol Psychiatry 1988;24:942-3.
89. Baetz M, Bowen RC. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 1998;43:73-7.
90. Lum M, Fontaine R, Elie R, Ontiveros A. Divalproex sodium's antipanic effect in panic disorder: a placebo-controlled study. Biol Psychiatry 1990;27:164A-165A.
91. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991;52:361-4.
92. Berigan TR, Holzgang A. Valproate as an alternative in posttraumatic stress disorder a case report. Mil Med 1995;160:318.
93. Brodsky L, Doerman AL, Palmer LS, Slade GF, Munasifi FA. Post traumatic stress disorder an eclectic approach. Int J Psychosom 1990;37:89-95.
94. Ford N. The use of anticonvulsants in posttraumatic stress disorder: case study and overview. J Trauma Stress 1996;9:857-63.
95. Szymanski HV, Olympia J. Divalproex in posttraumatic stress disorder. Am J Psychiatry 1991;148:1086-7.
96. Deltito JA. Valproate pretreatment for difficult-to-treat patient with OCD [letter]. J Clin Psychiatry 1994;55:500.
97. Cora-Locatelli G, Greenberg BD, Martin JD, Murphy DL. Valproate monotherapy in an SRI-Intolerant OCD patient [letter]. J Clin Psychiatry 1998;59:82.
98. Suzdak PE, Schwartz RD, Skolnick P, Paul SM. Ethanol stimulates GABA receptor-mediated chloride transport in rat brain synaptoneurosomes. Proc Natl Acad Sci USA 1986;83:4071-5.
99. Adinoff B. The alcohol withdrawal syndrome. Am J Addict 1994; 3:277-88.
100. Breier A, Paul S. The GABA-A/benzodiazepine receptor implications for the molecular basis of anxiety. J Psychiatr Res 1990;24:91-104.
101. Malcolm R, Ballenger JC, Sturgis ET. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry 1989;146:617-21.
102. Becker HC, Hale RL. Positive relationship between the number of previous ethanol withdrawal episodes and the severity of subsequent withdrawal seizures in mice. Psychopharmacology (Berl) 1994;116:26-32.
103. Adinoff B, O'Neill K, Ballenger JC. Alcohol withdrawal and limbic kindling. Am J Addict 1995;4:5-17.
104. Hillbom ME. The prevention of ethanol withdrawal seizures in rats by dipropylacetate. Neuropharmacology 1973;14:755-61.
105. Noble EP, Gillies R, Vigran R, Mandel P. The modification of the ethanol withdrawal syndrome in rats by di-n-propylacetate. Psychopharmacologia 1976;46:127-31.
106. Goldstein DB. Sodium bromide and sodium valproate: effective suppressants of ethanol withdrawal reactions in mice. J Pharmacol Exp Ther 1978;208:223-7.
107. Bastie Y. Suppression des crises d'epilepsie du sevrage par le depakine kans les cures de desintoxication ethylique. Ann Med Psychol (Paris) 1970;2:400-4.
108. Bonfiglio G, Falli S, Pacini A. Proposta di introduzione nella pratica ospedaliera di una nuova sostanza: il dipropilacetato di sodio nella prevenzione e terapia del delirium tremens alcoolico. Minerva Med 1977;68:42.33-45.
109. Tress W. Ein neuartiges therapieverfahren des alkoholischen entzugssyndroms. Therapiewoche 1977;27:9304-12.
110. Brasseur R. Depakine bei der behandlung des chronischen alkoholismus. Therapiewoche 1978;28:9981-4.
111. Lambie DG, Johnson RH, Vijayasenan ME, Whiteside EA. Sodium valproate in the treatment of the alcohol withdrawal syndrome. Aust N Z J Psychiatry 1980;14:213-5.
112. Rosenthal RN, Perkel C, Singh P, Anand O, Miner CR. A pilot open randomized trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal. Am J Addict 1998;7:189-97.
113. Hammer BA, Brady KT. Valproate treatment of alcohol withdrawal and mania [letter]. Am J Psychiatry 1996;153:1232.
114. Hillbom M, Tokola R, Kuusela V, Karkkainen P, Kalli-Lemma L, Pilke A, Kaste M. Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol 1989;6:223-6.
115. Bocci U, Beretta G. Esperienze sugli alcoolisti e tossicomani con dipropilacetato di sodio. Lavoro Neuropsichiatrico 1976;58: 51-61.
116. Minuk GY, Rockman GE, German GB, Duerksen DR, Borrett G, Hoeschen L. The use of sodium valproate in the treatment of alcoholism. J Addict Dis 1995;14:67-74.
117. Rickels K, Schweizer E, Garcia Espana F, Case G, DeMartinis N, Greenblatt D. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology (Berl) 1999; 141:1-5.
118. Roy-Byrne PP, Ward NG, Donnelly PJ. Valproate in anxiety and withdrawal syndromes. J Clin Psychiatry 1989;50:44-8.
119. Apelt S, Emrich HM. Sodium valproate in benzodiazepine withdrawal. Am J Psychiatry 1990;147:950-1.
120. Garbutt JC, van Kammen DP. The interaction between GABA and dopamine: implications for schizophrenia. Schizophr Bull 1983;9:336-53.
121. Wassef AA, Dott SG, Harris A, Brown A, O'Boyle M, Meyer WJ, Rose RM. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 1999;19:222-32.
122. Linnoila M, Viukari M, Hietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry 1976;129:114-9.
123. Nagao R, Ohshimo T, Mitsunobu K, Sato M, Otsuki S. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or druginduced tremor. Biol Psychiatry 1979;14:509-73.
124. Gundurewa VM, Beckmann H, Zimmer R, Ruther E. Effect of valproic acid on schizophrenic syndromes. Drug Res 1980;30:1212-3.
125. Altamura AC, Basile R, Mauri M, Cazzullo CL. Le valpromide dans le traitment d'etats psychotiques aigus: une etude clinique ouverte. Acta Psychiatr Belg 1986;86:297-304.
126. Morinigo A, Martin J, Gonzalez S, Mateo I. Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside J Clin Psychiatry 1989;11:199-207.
127. Chong SA, Tan CH, Lee EL, Liow PH. Augmentation of risperidone with valproic acid [letter]. J Clin Psychiatry 1998; 59:430.
128. Wassef A, Watson DJ, Morrison P, Bryant S, Flack J. Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. J Clin Psychopharmacol 1989;9:45-7.
129. Kausen J, Zimmermann P, Funfgeld EW, Klenke D, Henkel H. Effects of a GABA-mimetic drug (sodium valproate) on visually evoked potentials in chronic schizophrenics. Neuropsychobiology 1984;11:59-64.
130. Lautin A, Angrist B, Stanley M, Gershon S, Heckl K, Karobath M. Sodium valproate in schizophrenia: some biochemical correlates. Br J Psychiatry 1980;137:240-4.
131. Ko G, Korpi E, Freed W, Zalcman, SJ, Bigelow LB. Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients. Biol Psychiatry 1985;200: 199-228.
132. McElroy SL, Keck PE, Pope HG, Hudson JI. Treatment of psychiatric disorders with valproate: a series of 73 cases. Psychiatr Psychobiol 1988;3:81-5.
133. Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia revisited. Br J Psychiatry 1987;150:542-6.
134. Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 1998;31:122-5.
135. Casey DE, Hammerstad JP. Sodium valproate in tardive dyskinesia J Clin Psychiatry 1979;40:43-8.
136. Nair NVP, Lal S, Guyan H. Effects of GABAergic drugs on nigrostriatal and hypothalamic-pituitary dopaminergic systems. Brain Res Bull 1980;5:427-31.
137. Chien C, Jung K, Ross-Townsend A. Efficacies of agent related to GABA in treatment of tardive dyskinesia. Psychopharmacol Bull 1978;14:20-2.
138. Nasrallah HA, Dunner FJ, McCalley-Whitters M. A placebo-controlled trial of valproate in tardive dyskinesia. Biol Psychiatry 1985;20:205-28.
139. Friis T, Christensen TR, Geriach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia: a double-blind cross-over study with placebo. Acta Psychiatr Scand 1983;67:178-87.
140. Citrome L, Levine J, Allingham B. Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. Psychiatr Q 1998;69:283-300.
141. Kahn D, Stevenson E, Douglas CJ. Effect of sodium valproate in three patients with organic brain syndromes. Am J Psychiatry 1988;145:1010-1.
142. Pope HG, McElroy SL, Satlin A, Hudson JI, Keck PE, Kalish R. Head injury, bipolar disorder, and response to valproate. Compr Psychiatry 1988;29:34-8.
143. Abbas A, Styra R. Valproate prophylaxis against steroid induced psychosis. Can J Psychiatry 1994;39:188-9.
144. Stip E, Daoust L. Valproate in the treatment of mood disorder due to multiple sclerosis. Can J Psychiatry 1995;40:219-20.
145. RachBeisel JA, Weintraub E. Valproic acid treatment of AIDS-related mania. J Clin Psychiatry 1997;58:406-7.
146. Home M, Lindley SE. Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes. J Clin Psychiatry 1995;56:430-1.
147. Giakas WJ, Seibyl JP, Mazure CM. Valproate in the treatment of temper outbursts [letter]. J Clin Psychiatry 1990;51:525.
148. Geracioti TD. Valproic acid treatment of episodic explosiveness related to brain injury. J Clin Psychiatry 1994;55:416-7.
149. Wroblewski BA, Joseph AB, Kupfer J, Kalliel K. Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury. Brain Inj 1997;11:37-47.
150. Lott AD, McElroy SL, Keys MA. Valproate in the treatment of behavioral agitation in elderly patients with dementia. J Neuropsychiatry Clin Neurosci 1995;7:314-9.
151. Herrmann N. Valproic acid treatment of agitation in dementia. Can J Psychiatry 1998;43:69-72.
152. Hass S, Vincent K, Holt J, Lippman S. Divalproex: a possible treatment alternative for demented, elderly, aggressive patients. Ann Clin Psychiatry 1997;9:145-7.
153. Porsteinsson AP, Tariot PN, Erb R, Gaile S. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry 1997;5:344-51.
154. Kunik ME, Puryear L, Orengo CA, Molinari V, Workman RH. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances. Int J Geriatr Psychiatry 1998;13:29-34.
155. Narayan M, Nelson JC. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic. J Clin Psychiatry 1997;58:351-4.
156. Mellow AM. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol 1993;6:205-9.
157. Kastner R, Finesmith R, Walsh K. Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation. J Clin Psychopharmacol 1993;13:448-51.
158. Sovner R. The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders. J Clin Psychiatry 1989;50:40-3.
159. Whittier MC. Valproic acid for dysphoric mania in a mentally retarded adolescent. J Clin Psychiatry 1995;56:590-1.
160. Kastner T, Friedman D. Verapamil and valproic acid treatment of prolonged mania. J Am Acad Child Adolesc Psychiatry 1992; 31:271-5.
161. Mattes JA. Valproic acid for nonaffective aggression in the mentally retarded. J Nerv Mental Dis 1992;180:601-2.
162. Mazure CM, Druss BG, Cellar JS. Valproate treatment of older psychotic patients with organic mental syndromes and behavioral dyscontrol. J Am Geriatr Soc 1992;40:914-6.
163. Ruedrich S, Swales TP, Fossaceca C, Toliver J, Rutkowski A. Effect of divalproex sodium on aggression and self-injurious behavior in adults with intellectual disability: a retrospective review. J Intell Disabil Res 1999;43:105-11.
164. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988;45:111-9.
165. Stein DJ, Simeon D, Frenkel M, Islam MN, Hollander E. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995;56:506-10.
166. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry 1995;7:33-7.
167. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998;59:676-80.
168. Zarate CA, Tohen M, Narendran R, Tomassini EC, McDonald J, Sederer M, Madrid AR. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J Clin Psychiatry 1999;60:232-6.
169. Calabrese JR, Goethe JW, Kayser A, Marcotte DB, Monagin JA, Kimmel SE, Brugger AM, Morris D, Fatemi SH. Adverse events in 583 valproate-treated patients. Depression 1996;3:257-62.
170. Balfour JA, Bryson HM. Valproic acid: a review of its pharmacology and therapeutic potential in indications other than epilepsy. CNS Drugs 1994;2:144-73.
171. Vainionpaa LK, Rattya J, Knip M, Tapanainen JS, Pakarinen AJ, Lanning P, Tekay A, Myllyla VV, Isojarvi JIT. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999;45:444-50.
172. Isojarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla W. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84.
173. Kennedy D, Koren G. Valproic acid use in psychiatry: issues in treating women of reproductive age. J Psychiatry Neurosci 1998;23:223-8.
174. Bowden CL. The use of mood stabilizers in the treatment of psychiatric disorders. J Clin Psychiatry 1999;60[suppl 5]:3-4.
175. Maes M, Calabrese JR. Mechanisms of action of valproate in affective disorders. In: Joffe RT, Calabrese JR, eds. Anticonvulsants in mood disorders. New York: Marcel Dekker, 1994:93-110.
176. Petty F, Rush AJ, Davis JM, Calabrese JR, Kimmel SE, Kramer GL, Small JG, Miller MJ, Swann AE, Orsulak PJ, Blake ME, Bowden CL. Plasma GABA predicts acute response to divalproex in mania. Biol Psychiatry 1996;39:278-84.
177. Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982;19:315-59.
178. Rimmer EM, Richens A. An update on sodium valproate. Pharmacotherapy 1985;5:171-84.
179. Petty F, Kramer GL, Fulton M, Moeller FG, Rush AJ. Low plasma GABA is a trait-like marker for bipolar illness. Neuropsychopharmacology 1993;9:125-32.
180. Berrettini WH, Nurnberger JI, Hare T, Gershon ES, Post RM. Plasma and CSF GABA. in affective illness. Br J Psychiatry 1982;141:483-7.
181. Berrettini WH, Nurnberger JI, Hare TA, Simmons-Alling S, Gershon ES. CSF GABA in euthymic manic-depressive patients and controls. Biol Psychiatry 1986;21:842-4.
182. Petty F. GABA mechanisms in learned helplessness. In: Bartholini G, ed. LERS monograph series: GABA and mood disorders: experimental and clinical research. 4th ed. New York: Raven Press, 1986:61-6.
183. Lloyd KG, Pichat P. Decrease in GABA-B binding in the frontal cortex of olfactory bulbectomized rats. Br J Pharmacol 1985;87:36P.
184. Dennis T, Beauchemin V, Lavoie N. Antidepressant-induced modulation of GABA(A) receptors and beta-adrenoceptors but not GABA(B) receptors in the frontal cortex of olfactory bulbectomised rats. Eur J Pharmacol 1994;262:143-8.
185. Honig A, Bartlett JR, Bouras N, Bridges PK. Amino acid levels in depression: a preliminary investigation. J Psychiatr Res 1989; 22:159-64.
186. Cross JA, Cheetham SC, Crompton MR, Katona CLE, Horton RW. Brain GABA-B binding sites in depressed suicide victims. Psychiatry Res 1988;26:119-29.
187. Gerner RH, Hare TA. CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa. Am J Psychiatry 1981;138:1098-101.
188. Post RM, Ballenger JC, Hare TA, Goodwin FK, Lake CR. Jimerson DC, Bunney WE Jr. Cerebrospinal fluid GABA in normals and patients with affective disorders. Brain Res Bull 1980; 5[suppl 2]:755-9.
189. Petty F, Kramer GL, Gullion CM, Rush AJ. Low plasma gamma-aminobutyric acid levels in male patients with depression. Biol Psychiatry 1992;32:354-63.
190. Shukla GS. Combined lithium and valproate treatment and subsequent withdrawal: serotonergic mechanism of their interaction in discrete brain regions. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:153-6.
191. Whitton PS, Fowler LJ. The effect of valproic acid on 5-hydroxytryptamine and 5-hydroxyindoleacetic acid concentration in hippocampal dialysates in vivo. Eur J Pharmacol 1991;200: 167-9.
192. Baf MHM, Subhash MN, Lakshmana KM, Rao BSSR. Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem Int 1994;24:67-72.
193. Biggs CS, Pearce BR, Fowler LJ, Whitton PS. The effect of sodium valproate on extracellular GABA and other amino acids in the rat ventral hippocampus: an in vivo microdialysis study. Brain Res 1992;594:138-42.
194. Biggs CS, Pearce BR, Fowler LJ, Whitton PS. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem 1992;59:1702-8.
195. Kempf E, Mack G, Schleef C, Mandel P. Effect of valproic acid on brain serotonin metabolism in isolated and grouped rats. Pharmacol Biochem Behav 1982;17:49-52.
196. Loscher W, Honack D. Valproate and its major metabolite e-2-en-valproate induce different effects on behaviour and brain monoamine metabolism in rats. Eur J Pharmacol 1996;299: 61-7.
197. Stein MB, Uhde TW. Panic disorder and major depression: lifetime relationship and biological markers. In: Ballenger JC, ed. Clinical aspects of panic disorder. New York: Wiley-Liss, 1990: 151-68.
198. Maes M, Meltzer HY. The serotonin hypothesis of depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:933-44.
199. Goddard AW, Woods SW, Charney DS. A critical review of the role of norepinephrine in panic disorder: focus on its interaction with serotonin. In: Westenberg HGM, Boer AD, Murphy DL, eds. Advances in the neurobiology of anxiety disorders. New York: John Wiley & Sons, 1996:107-37.
200. Davis LL, Kramer GL, Rush AJ, Petty F. Biological trait markers of depression. In: Panksepp J, ed. Advances in biological psychiatry. 2nd vol. Greenwich, CT: JAI Press, 1996:115-51.
201. Davis LL, Suris A, Lambert M, Heimberg C, Petty F. Posttraumatic stress disorder and serotonin: new directions for research and treatment. J Psychiatry Neurosci 1997;22:318-26.
202. Petty F, Davis LL, Kabel D, Kramer GL. Serotonin dysfunction disorders: a behavioral neurochemistry perspective. J Clin Psychiatry 1996;57:11-6.
203. Wilcox J. Divalproex sodium in the treatment of aggressive behavior. Ann Clin Psychiatry 1994;6:17-20.
204. Donovan SJ, Susser ES, Nunes EV, Stewart JW, Quitkin FM, Klein DF. Divalproex treatment of disruptive adolescents: a report of 10 cases. J Clin Psychiatry 1997;58:12-5.